Expertise in
7
conditions

Dr. Harsha V. Poola

Hematology
Ascension Saint Mary?S Hospital
2251 N Shore Dr, 
Rhinelander, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
7
conditions
Ascension Saint Mary?S Hospital
2251 N Shore Dr, 
Rhinelander, WI 

Overview

Harsha Poola is a Hematologist practicing medicine in Rhinelander, Wisconsin.

Dr. Poola is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, ALK-Positive Non-Small Cell Lung Cancer, Agranulocytosis, and Pulmonary Embolism.

He is actively involved in clinical research, participating in 7 clinical trials. Dr. Poola is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WI

Hospital Affiliations

Thedacare Regional Medical Center - Appleton Inc
Thedacare Regional Med Ctr - Neenah
St Marys Hospital Medical Ctr
Thedacare Medical Center - Berlin Inc
St Vincent Hospital

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ascension Saint Mary?S Hospital
2251 N Shore Dr, Rhinelander, WI 54501

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Implementation and Effectiveness Trial of HN-STAR
Implementation and Effectiveness Trial of HN-STAR
Enrollment Status: Completed
Publish Date: July 24, 2026
Intervention Type: Other
Study Phase: Not Applicable
View 5 Less Clinical Trials
Similar Doctors
Expertise in
36
conditions
Dr. Niaz M. Haque
Hematology | Oncology
Expertise in
36
conditions
Dr. Niaz M. Haque
Hematology | Oncology
Referral may be required

Aspirus Regional Cancer Center

215 N 28th Ave, 
Wausau, WI 
 (48.8 miles away)
715-847-2866
Languages Spoken:
English, Bengali, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Niaz Haque is a Hematologist and an Oncologist practicing medicine in Wausau, Wisconsin. Dr. Haque is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Cervical Cancer, and Bone Marrow Aspiration. Dr. Haque is currently accepting new patients.

Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

Office

3301 Cranberry Blvd, 
Schofield, WI 
 (52.6 miles away)
715-393-3886
Languages Spoken:
English
See accepted insurances

Douglas Reding is a Hematologist practicing medicine in Schofield, Wisconsin. Dr. Reding is highly rated in 1 condition, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Essential Thrombocythemia, B-Cell Lymphoma, and Chronic Myelomonocytic Leukemia (CMML).

Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required

Aspirus Regional Cancer Center

215 N 28th Ave, 
Wausau, WI 
 (48.8 miles away)
715-847-2866
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Mckenna is a Hematologist practicing medicine in Wausau, Wisconsin. He has been practicing medicine for over 10 years. Dr. Mckenna is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Chronic Graft Versus Host Disease (cGvHD), Gastroesophageal Junction Cancer, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Mckenna is currently accepting new patients.

Frequently Asked Questions about Dr. Harsha V. Poola

How do I make an appointment with Dr. Harsha V. Poola?

You can book an appointment with Dr. Harsha V. Poola by calling their office at 715-361-2140. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Harsha V. Poola a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Harsha V. Poola is classified as an Advanced expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Harsha V. Poola specialize in?

While Dr. Harsha V. Poola is a Hematology, they have specific expertise in Thrombocytopenia, ALK-Positive Non-Small Cell Lung Cancer, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Harsha V. Poola accept my insurance?

Dr. Harsha V. Poola accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 715-361-2140 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Poola's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 68 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile